Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: spinynorman1323 who wrote (786)	5/17/1999 11:27:00 AM
From: Jibacoa	Respond to of 2344

The Bid-Ask is not looking good. 1 vs. 50 at present levels

To: spinynorman1323 who wrote (786)	5/17/1999 11:29:00 AM
From: StockMiser	Respond to of 2344

Here is something of interest...Stock Analysis - Articles weeklystockpicks.com Updated Monday, May 17, 1999 BIOMIRA INC. (BIOM) Over the years we have waged a huge campaign to help fight one of the leading causes of death in the United States and around the world. This wretched disease we are referring to is Cancer. In addition many biotechnology and drug companies continue to make great strides and advances in the treatment and cure for the disease. Many of the corporations that help to battle Cancer you probably have heard of, but there is a handful of smaller companies, not as well known, who are making great advances as well. In a previously reported story this week we had mentioned a company by the name of Matrix Pharmaceutical (MTX). In the story we had described to you that Matrix (a reasonably unknown drug company) had been developing a new treatment for head and neck cancer known as Intradose. We than exclaimed the drug had been granted fast track review by the U.S. Food and Drug Administration (FDA). In late breaking news over the weekend a company by the name of Biomira (BIOM) had added increased optimism to help fight the disease. A new study from the Fred Hutchinson Cancer Research center (which is an independent, non-profit research institution dedicated to development and advancement of biomedical technology to eliminate cancer and other fatal diseases) indicated that the administration of Biomira's cancer vaccine, Theratope, following autologous stem cell transplant can increase survival and decrease relapse in ovarian and breast cancer patients when compared to the stem cell transplant alone. The vaccine induces the body's immune system to help fight the cancerous cells. The data was presented on May 15, 1999 at the 35th annual meeting of the American Society of Clinical Oncology (the largest professional meeting of clinical data on new cancer treatments) in Atlanta, which continues through May 18th. The Research team at the Fred Hutchinson Cancer Research Center, led by Leona Holmberg, M.D.,Ph.D., and Brenda Sandmaier, M.D., treated 40 cancer patients between September 1, 1995 and November 18, 1997. All 40 patients received chemotherapy followed by autologous stem cell transplantation and only 26 received the Theratope vaccine. The results indicated that the chance of death was more than 2 times as great for the people who had not received the vaccine than those who had. Also the chance of relapse was approximately 1.7 times greater for patients who had not received the Theratope vaccine and remission for those who had was longer. The cancer vaccine is currently being evaluated in a Phase III clinical trial which will involve 900 patients with metastatic breast cancer at approximately 75 sites worldwide In looking in to the technical analysis of the company we at the WSP see something promising. The stock has recently risen slightly after establishing a long-term base at its low of about 1 ½. This rise in share price was accompanied by a significant increase of on balance volume. In addition, the stock has crossed its 50-day moving average, is above its 200 day moving average, and is currently trading at the edge of the upper Bollinger Band. This price movement may truly be meaningful, and represent an advance that has a high probability of being sustained. Federal drug administration approvals are long processes and many more drugs do not receive approval more than do, but this is a company that appears to be at the fore front of something very promising. Keep a close eye on this security in the following year to come. Recent Price: $5.375 52 Week High: $17.125 52 Week Low: $1.188 Market Capitalization: $238.3 Mil Shares Outstanding: 44.3 Mil Float: 41.7 Mil After Tax Income: -14.2 Mil Sales: -5.87 Mil EPS: - .09 Annual EPS: 1996=-.43, 1997=-.33, 1998=-.33 PE: N/A